JP Morgan downgrades RxSight on market, competitive pressures
Investing.com -- JP Morgan downgraded RxSight to Underweight, citing market, economic, and competitive headwinds that have led to a weaker-than-expected first-quarter performance and a downward revision to 2025 guidance. The firm set a $17 price target on the stock.